A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia | NCT01850641 | Trialant
CompletedInterventionalPhase 3Updated Oct 9, 2018
A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
ClinicalTrials.gov ID
NCT01850641
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
35Actual
Last Update Posted
Oct 9, 2018Actual
Start Date
Apr 29, 2013Actual
Primary Completion Date
Dec 2013Actual
Completion Date
Dec 3, 2013Actual
Brief Summary
The purpose of this study is to investigate the safety and efficacy when administering PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.
Hemodialysis
Hyperphosphatemia
PA21
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Receiving stable maintenance hemodialysis 3 times a week
Dialysis patients with hyperphosphatemia
Exclusion Criteria:
Patients having history of a pronounced brain / cardiovascular disorder